Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Dylan Boyd

Nurse Practitioner, Acute Care Hattiesburg, MS Nurse Practitioner

NPI 1891357588 CMS profile 10792520

415 S 28Th Ave, Hattiesburg, MS 39401

Open in the dashboard

General payments

$15,051

842 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dylan Boyd of Hattiesburg, MS is reported in the CMS Open Payments database as having received $15,051 across 842 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,054 212
2024 General $3,584 194
2023 General $3,507 197
2022 General $2,707 162
2021 General $1,198 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dylan Boyd
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Dylan Boyd were reported at $4,054. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Dylan Boyd Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,198 $123 $38–$327 $132
2022 $2,707 $130 $44–$369 $149
2023 $3,507 $144 $49–$410 $160
2024 $3,584 $146 $48–$433 $164
2025 $4,054 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $3,083 138 payments
  2. GlaxoSmithKline, LLC. $2,039 175 payments
  3. Mylan Specialty L.P. $1,107 58 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $973 60 payments
  5. Grifols USA, LLC $969 51 payments
  6. Genzyme Corporation $743 36 payments
  7. Regeneron Healthcare Solutions, Inc. $558 24 payments
  8. United Therapeutics Corporation $499 26 payments
  9. Viatris Specialty LLC $454 32 payments
  10. Jazz Pharmaceuticals Inc. $451 20 payments
  11. Other $4,176 222 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $15,008 841 payments
  2. Education $43 1 payment
Products named General payments · program years 2021–2025
  1. TEZSPIRE $1,813 72 payments
  2. YUPELRI $1,561 90 payments
  3. FASENRA $1,458 52 payments
  4. TRELEGY ELLIPTA $1,443 129 payments
  5. Prolastin-C Liquid $969 51 payments
  6. OFEV $783 46 payments
  7. DUPIXENT $743 36 payments
  8. BREZTRI $706 13 payments
  9. NUCALA $596 46 payments
  10. AIRSUPRA $524 6 payments
  11. Other $7,264 385 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

4,195

Median for Nurse Practitioner: 389

Drug cost

$1,429,618

Median for Nurse Practitioner: $21,885

Branded share of claims

74.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 718 $581,662
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 235 $182,950
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 218 $142,664
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 215 $108,707
Spiriva Respimat Tiotropium Bromide Brand 133 $100,873
Breo Ellipta Fluticasone/Vilanterol Brand 204 $92,709
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 59 $37,419
Incruse Ellipta Umeclidinium Bromide Brand 82 $28,861
Albuterol Sulfate Hfa Albuterol Sulfate Brand 760 $28,325
Symbicort Budesonide/Formoterol Fumarate Brand 99 $26,504

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$78,326

Of which drugs: $3,224

Medicare patients

726

Average age 74

Services billed

2,015

325 women, 401 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 71%
Arthritis 58%
Ischemic heart disease 56%
Diabetes 42%
Depression 34%
Heart failure 31%
Atrial fibrillation 31%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 27 27 $2,199
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 18 53 $281

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEZSPIRE
$487 — —
YUPELRI
$440 — —
DUPIXENT
$429 — —
TRELEGY ELLIPTA
$304 718 —
Prolastin-C Liquid
$229 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

842 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Acute Care in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record